Annual Report

Overview

The report presents Brii Biosciences' first ESG report for 2021, highlighting approval of its amubarvimab/romlusevimab COVID-19 antibody combination by China's NMPA. It also reports a global workforce of 113 employees and describes governance, materiality analysis, employee initiatives, and office-based environmental KPIs.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Publication date: 23 March 2022
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services